Voyager Therapeutics, Inc. Earnings Per Share Diluted

• Voyager Therapeutics, Inc. showed a decrease of -80.5% in Earnings Per Share Diluted from 2024 to 2025.
• This data is from Voyager Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2018: $0.80 (loss) per share | Q2 2019: $0.29 per share | Q3 2019: $0.41 (loss) per share | Q2 2020: $0.23 (loss) per share | Q3 2020: $2.27 per share | Q1 2021: $0.58 (loss) per share | Q2 2021: $0.80 (loss) per share | Q3 2021: $0.67 (loss) per share | Q1 2022: $0.56 (loss) per share | Q2 2022: $0.50 (loss) per share | Q3 2022: $0.45 per share | Q1 2023: $2.94 per share | Q2 2023: $0.51 (loss) per share | Q3 2023: $0.59 (loss) per share | Q1 2024: $0.20 (loss) per share | Q2 2024: $0.18 (loss) per share | Q3 2024: $0.16 (loss) per share | Q1 2025: $0.53 (loss) per share | Q2 2025: $0.57 (loss) per share | Q3 2025: $0.47 (loss) per share.
• Over the full 8 years of available data (2018 to 2025), Voyager Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 25.8%.
• Historical annual values: Fiscal year 2025: $2.04 (loss) per share | Fiscal year 2024: $1.13 (loss) per share | Fiscal year 2023: $2.97 per share | Fiscal year 2022: $1.21 (loss) per share | Fiscal year 2021: $1.89 (loss) per share | Fiscal year 2020: $0.98 per share | Fiscal year 2019: $1.21 (loss) per share | Fiscal year 2018: $2.75 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026